Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137800 · ClinicalTrials.gov registry record · Phase 2
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 2
- Study locations
NCT00137800 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 82 participants, below the 233-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00137800, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.
Conditions Studied
Interventions
- DRUG OSI-774 (Tarceva)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2003-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137800
The ClinicalTrials.gov registry entry for NCT00137800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (65% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which OSI-774 (Tarceva) is the first listed.
NCT00137800 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00137800 about?
NCT00137800 is a clinical study titled "Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients". The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.
What is the current status of trial NCT00137800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2003-02. Estimated completion is 2007-03.
What conditions does trial NCT00137800 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00137800?
The interventions under investigation include: OSI-774 (Tarceva) (DRUG).
Who is sponsoring clinical trial NCT00137800?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00137800 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
-
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.